Technology
Health
Biotechnology

Minerva Neurosciences

$6.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.16 (-2.45%) As of 10:43 AM EDT today
-$0.16 (-2.45%) Today

Why Robinhood?

You can buy or sell NERV and other stocks, options, ETFs, and crypto commission-free!

About NERV

Minerva Neurosciences, Inc Common Stock, also called Minerva Neurosciences, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. Read More The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.

Employees
13
Headquarters
Waltham, Massachusetts
Founded
2007
Market Cap
254.84M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
346.92K
High Today
$6.58
Low Today
$6.32
Open Price
$6.51
Volume
241.55K
52 Week High
$12.95
52 Week Low
$4.07

Collections

Technology
Health
Biotechnology
2014 IPO
US
North America

NERV News

MarketWatchJun 24

UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals

885

NERV Earnings

-$0.41
-$0.35
-$0.30
-$0.24
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market

More NERV News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.